Embryonic stem cell trials for macular degeneration: a preliminary report

@article{Schwartz2012EmbryonicSC,
  title={Embryonic stem cell trials for macular degeneration: a preliminary report},
  author={Steven D. Schwartz and Jean-Pierre Hubschman and Gad Heilwell and Valentina Franco-C{\'a}rdenas and Carolyn K. Pan and Rosaleen M Ostrick and Edmund Mickunas and Roger Gay and Irina V. Klimanskaya and Robert Lanza},
  journal={The Lancet},
  year={2012},
  volume={379},
  pages={713-720}
}

Figures from this paper

Human embryonic stem cell-derived retinal pigment epithelial cell transplantation for retinal degeneration

Promising results suggest that hESC-derived RPE cells could represent a novel treatment paradigm for retinal degenerations hallmarked by tissue loss or dysfunction.

Embryonic stem cells as a treatment for macular degeneration

The pathophysiologic case for RPE transplantation with stem cell (SC)-derived tissue is presented, a review of the preclinical data substantiating the hypothesis and the initial clinical trials safety data from early human trials are reviewed.

Stem Cell Treatment for Age-Related Macular Degeneration: the Challenges.

The RPE rip scenario perhaps provides the ideal scenario for RPE replacement using stem cells as a mechanism of preventing photoreceptor loss, and the extent to which the promise of stem cell treatment for AMD will be fulfilled is discussed.

A Preclinical Safety Study of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells for Macular Degeneration.

It is concluded that transplanted CR-4 hES-derived RPE cells are well tolerated in immunosuppressed healthy and dystrophic murine retinas in age-related macular degeneration.

Human embryonic stem cell-derived retinal pigment epithelium transplants as a potential treatment for wet age-related macular degeneration

Visual and physiological testing indicated limited functional improvement, albeit to different degrees between patients, and some promising early results concerning the use of transplanted hESC-RPE cells to alleviate wet-AMD are provided.

Stem cells in clinical trials for treatment of retinal degeneration

  • H. Klassen
  • Medicine, Biology
    Expert opinion on biological therapy
  • 2016
This review considers the scientific work and early trials with fetal cells and tissues that set the stage for the current clinical investigatory work, as well the trials themselves, specifically those either now completed, underway or close to initiation.

Stem Cell Therapy for the Treatment of Dry Age-Related Macular Degeneration

RPE stem cell grafts show great promise in restoring vision in patients with geographic atrophy due to AMD, as limited clinical trials in humans have already shown positive results, and more results are forthcoming.
...

References

SHOWING 1-10 OF 35 REFERENCES

Human embryonic stem cell-derived cells rescue visual function in dystrophic RCS rats.

Embryonic stem cells promise to provide a well-characterized and reproducible source of replacement tissue for human clinical studies and batches of RPE derived from NIH-approved hES cells were tested and shown capable of extensive photoreceptor rescue in an animal model of retinal disease.

Long‐Term Safety and Function of RPE from Human Embryonic Stem Cells in Preclinical Models of Macular Degeneration

Long‐term data showed no gross or microscopic evidence of teratoma/tumor formation after subretinal hESC‐RPE transplantation, suggesting that hESCs could serve as a potentially safe and inexhaustible source of RPE for the efficacious treatment of a range of retinal degenerative diseases.

Outcome of transplantation of autologous retinal pigment epithelium in age-related macular degeneration: a prospective trial.

Evidence is provided that autologous transplantation of RPE is a beneficial supplement to membrane excision alone in patients with fCNV in age-related macular degeneration and may be regarded as a reasonable treatment option.

Iris pigment epithelial cell translocation in exudative age-related macular degeneration

Preliminary data suggests that IPE translocation in submacular surgery for ARMD can preserve but not improve preoperative visual acuity over 6 months, and functional results are promising compared toSubmacular membrane extraction alone and RPE transplantation.

Transplantation of fetal retinal pigment epithelium in age-related macular degeneration with subfoveal neovascularization

Human fetal RPE transplants survive well in the macula for as long as 3 months and are capable of growing to cover epithelial defects caused by removal of subretinal neovascular membranes.

Concise Review: Toward Stem Cell‐Based Therapies for Retinal Neurodegenerative Diseases

This concise review will examine how cell therapies are being applied experimentally for neuroregenerative and neuroprotective treatment of currently incurable degenerative retinal diseases.

Iris pigment epithelial translocation in the treatment of exudative macular degeneration: a 3-year follow-up.

The results suggest that iris pigment epithelial cells may serve as a substitute for retinal pigment epithelium cells after choroidal neovascularization removal in patients with exudative macular degeneration; however, whether these cells will be of any value for the restoration of vision and possible protection against choroid neov vascularization recurrence awaits further clinical observation and additional research.

Transplantation of autologous iris pigment epithelium after removal of choroidal neovascular membranes.

Autologous IPE cells may be used as a substitute for autologous RPE cells to transplant to the subretinal space to treat age-related macular degeneration and improve or stable visual acuity in 18 patients after IPE transplantation.